sketch2.jpg

Transformational Therapies Targeting Protein Degradation

Pioneering Tuneable Small-Molecule Degradation Platform

Dunad Therapeutics is focusing on the development of next-generation targeted protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tuneable mono-valent small molecules, unlocking new target space and allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.

 
back-science.png

Our Science

Dunad’s unique small molecule platform induces targeted degradation of disease-causing proteins via direct modulation of the target protein’s surface topology. The Company’s novel molecular approach, based on mono-valent small molecules, is fully tuneable to be exquisitely selective for the target, and is underpinned by a target-class agnostic mechanism of action that is distinct from traditional mechanisms of targeted protein degradation. 

Our Platform

The Company’s drug pipeline is powered by its expanding 4-pillar proprietary platform:   

Expanding the frontiers of our plug-and-play mono-valent degrader platform

Icon-1.png

Proprietary
Degradation Technology

Accelerating Hit ID against novel

targets

Icon-2.png

Proprietary Screening Library

Proteomics Workflow

Unlocking previously inaccessible degradation targets via global and multi-dimensional profiling of the proteome

Driving the best drug candidates through the development 

Icon-3.png

Bioinformatics Pipeline

 
Untitled-1.png

Our Pipeline

Dunad is focusing on targets for which degradation is the optimal mechanism of action, and inhibition of the target’s activity alone is insufficient to elicit the maximum therapeutic effect.

While the unique MOA and compositions of our platform are expected to unlock access to the previously undruggable targets, our platform also enables development of orally bioavailable and CNS-accessible degrader therapeutics, together expanding the frontiers of protein degradation space.

 

Our Team

Dunad is continuing to expand its world-class scientific team with expertise across protein degradation, covalent therapeutics and proteomics, as well as it’s business leadership team.

Executive Team

PATRICK GUNNING, PhD

Founder, acting CEO, CSO

DIANA KRASKOUSKAYA, PhD

Founder,
COO

GRAHAM SIMPSON, PhD

SVP Drug

Discovery

TEAM-ILLUSTRATION.png

Scientific Team

MARGARET DANIEL

Chief Financial Officer

ELIZABETH ROPER, PhD

Director

BERNHARD KUSTER, PhD

Proteomics

Ian_2.png

IAN COLLINS, PhD

Protein Degradation,
Medicinal Chemistry 

JEFF KEILLOR, PhD

Targeted Covalent Therapeutics

MIKE MAZANETZ, PhD

PETER HUNT, PhD

Computational Chemistry

Computational

Chemistry

JANE DANCER, PhD

Business Development Adviser

 

Our Investors

Dunad is backed by Epidarex Capital, a leading transatlantic venture capital firm with a track record of building exceptional life science companies in emerging hubs in the US and UK. For more information, visit www.epidarex.com.

 

Explore a career at Dunad

We’re hiring! Come work with our passionate team, pushing the boundaries of what small molecules are capable of

 

Contact Us

Thanks for submitting!